Structure Therapeutics Secures Nature Medicine Publication and ADA 2026 Spotlight for Aleniglipron, Setting Stage for Q3 Phase 3 Trial
On June 5, 2026, Structure Therapeutics Inc. (NASDAQ: GPCR) announced the publication of its Phase 2b ACCESS clinical trial results in Nature Medicine, concurrently with an oral presentation at the American Diabetes Association's (ADA) 86th Scientific Sessions. The published data provides strong clinical validation for aleniglipron (GSBR-1290), the company's once-daily oral small-molecule GLP-1 receptor agonist, highlighting its competitive efficacy, sustained weight loss, and an improved tolerability profile that supports its upcoming Phase 3 initiation in Q3 2026.
Key Clinical Findings from the ACCESS Program
The publication, titled "Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial," detailed results from the core 36-week double-blind study and a predefined interim analysis of its open-label extension (OLE) safety study:
- Efficacy and Continued Weight Loss: At Week 36, all three maintenance dose levels (45 mg, 90 mg, and 120 mg) achieved statistically significant reductions in body weight, meeting the primary and all key secondary endpoints. Crucially, patients in the OLE continued to lose weight beyond 36 weeks with no apparent plateau.
- OLE Weight Loss Metrics: The interim OLE analysis showed total body weight reductions of 13.3% (for patients transitioning from the 45 mg cohort), 16.2% (90 mg cohort), and 15.3% (120 mg cohort) after a median follow-up of 20 weeks in the extension phase.
- Tolerability and Discontinuations: Aleniglipron demonstrated a favorable tolerability profile, with an overall low discontinuation rate of 10.4%. Gastrointestinal (GI) adverse events were mild-to-moderate and primarily occurred during the initial titration phase. Heat-map analysis revealed that even if patients experienced vomiting, it rarely recurred upon dose re-initiation or subsequent up-titration.
- Phase 3 Protocol Optimization: To further optimize GI tolerability, Structure is introducing a lower 2.5 mg starting dose for its Phase 3 registration program, which remains on track to initiate in Q3 2026.
In addition to aleniglipron monotherapy, Structure presented preclinical data at ADA 2026 demonstrating that combining oral aleniglipron with their small-molecule amylin receptor agonist (ACCG-2671) led to enhanced weight loss in obese non-human primates (NHPs) compared to either treatment alone, signaling a robust multi-pathway pipeline.
As of June 22, 2026, GPCR has a market capitalization of $3.16 billion with $316.2 million in cash against $5.8 million in total debt, positioning the company with a solid balance sheet to fund its upcoming registrational trials.
Verbatim Quotes
- From GlobeNewswire:
"The interim analysis from the OLE study showed that patients continued to lose weight after a median follow up of 20 weeks, with weight loss of 13.3%, 16.2%, and 15.3% in the participants coming from 45 mg, 90 mg, and 120 mg aleniglipron arms from the double-blind treatment period, respectively."
- From Blai Coll, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics, in GlobeNewswire:
"We are on track to initiate our Phase 3 program of aleniglipron in the third quarter of 2026 with a starting dose of 2.5 mg and the intent to evaluate multiple doses based on this data and our End of Phase 2 meeting with the FDA."